Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v6-FR
Language English French
Date Updated 2023-06-20 2023-06-19
Drug Identification Number 01953583 01953583
Brand name PHENYLEPHRINE HYDROCHLORIDE INJECTION USP PHENYLEPHRINE HYDROCHLORIDE INJECTION USP
Common or Proper name PHENYLEPHRINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients PHENYLEPHRINE PHENYLEPHRINE
Strength(s) 10MG 10MG
Dosage form(s) LIQUID LIQUID
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 5ML 10LIVI 5ML 10LIVI
ATC code C01CA C01CA
ATC description CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2023-06-12 2023-06-12
Estimated end date 2023-06-23 2023-06-23
Actual end date 2023-06-19 2023-06-19
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments